vs
IMMUCELL CORP（ICCC）与QuidelOrtho Corp（QDEL）财务数据对比。点击上方公司名可切换其他公司
QuidelOrtho Corp的季度营收约是IMMUCELL CORP的127.1倍（$699.9M vs $5.5M）。IMMUCELL CORP净利率更高（-2.5% vs -104.7%，领先102.2%）。QuidelOrtho Corp同比增速更快（-3.7% vs -8.4%）。IMMUCELL CORP自由现金流更多（$-1.8M vs $-94.7M）。过去两年IMMUCELL CORP的营收复合增速更高（3.9% vs -2.9%）
ImmuCell Corp是一家总部位于美国的动物健康生物技术企业，主要研发、生产和销售以奶牛为主的家畜相关保健与治疗产品，核心产品包括乳腺炎等常见牛类疾病的防治方案，主要服务北美地区的畜牧养殖户和兽医机构。
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
ICCC vs QDEL — 直观对比
营收规模更大
QDEL
是对方的127.1倍
$5.5M
营收增速更快
QDEL
高出4.7%
-8.4%
净利率更高
ICCC
高出102.2%
-104.7%
自由现金流更多
ICCC
多$92.9M
$-94.7M
两年增速更快
ICCC
近两年复合增速
-2.9%
损益表 — Q3 2025 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $5.5M | $699.9M |
| 净利润 | $-139.7K | $-733.0M |
| 毛利率 | 42.9% | — |
| 营业利润率 | 0.4% | -100.7% |
| 净利率 | -2.5% | -104.7% |
| 营收同比 | -8.4% | -3.7% |
| 净利润同比 | 80.1% | -3583.4% |
| 每股收益（稀释后） | $-0.02 | $-10.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICCCQDEL
| Q3 25 | $5.5M | $699.9M | ||
| Q2 25 | $6.4M | $613.9M | ||
| Q1 25 | $8.1M | $692.8M | ||
| Q4 24 | $7.8M | $707.8M | ||
| Q3 24 | $6.0M | $727.1M | ||
| Q2 24 | $5.5M | $637.0M | ||
| Q1 24 | $7.3M | $711.0M | ||
| Q4 23 | $5.1M | $742.6M |
净利润ICCCQDEL
| Q3 25 | $-139.7K | $-733.0M | ||
| Q2 25 | $501.9K | $-255.4M | ||
| Q1 25 | $1.4M | $-12.7M | ||
| Q4 24 | — | $-178.4M | ||
| Q3 24 | $-701.7K | $-19.9M | ||
| Q2 24 | $-1.5M | $-147.7M | ||
| Q1 24 | $-437.9K | $-1.7B | ||
| Q4 23 | — | $7.0M |
毛利率ICCCQDEL
| Q3 25 | 42.9% | — | ||
| Q2 25 | 43.7% | — | ||
| Q1 25 | 41.6% | — | ||
| Q4 24 | 36.5% | — | ||
| Q3 24 | 26.3% | — | ||
| Q2 24 | 22.5% | — | ||
| Q1 24 | 31.6% | — | ||
| Q4 23 | 24.7% | — |
营业利润率ICCCQDEL
| Q3 25 | 0.4% | -100.7% | ||
| Q2 25 | 8.8% | -29.4% | ||
| Q1 25 | 13.9% | 4.7% | ||
| Q4 24 | 8.0% | -14.2% | ||
| Q3 24 | -9.6% | 2.1% | ||
| Q2 24 | -25.3% | -18.4% | ||
| Q1 24 | -4.1% | -247.3% | ||
| Q4 23 | -19.7% | 5.4% |
净利率ICCCQDEL
| Q3 25 | -2.5% | -104.7% | ||
| Q2 25 | 7.8% | -41.6% | ||
| Q1 25 | 17.9% | -1.8% | ||
| Q4 24 | — | -25.2% | ||
| Q3 24 | -11.7% | -2.7% | ||
| Q2 24 | -28.0% | -23.2% | ||
| Q1 24 | -6.0% | -239.9% | ||
| Q4 23 | — | 0.9% |
每股收益（稀释后）ICCCQDEL
| Q3 25 | $-0.02 | $-10.78 | ||
| Q2 25 | $0.06 | $-3.77 | ||
| Q1 25 | $0.16 | $-0.19 | ||
| Q4 24 | $0.09 | $-2.54 | ||
| Q3 24 | $-0.09 | $-0.30 | ||
| Q2 24 | $-0.20 | $-2.20 | ||
| Q1 24 | $-0.06 | $-25.50 | ||
| Q4 23 | $-0.15 | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.9M | $98.1M |
| 总债务越低越好 | $9.5M | $2.5B |
| 股东权益账面价值 | $29.8M | $2.0B |
| 总资产 | $45.7M | $5.7B |
| 负债/权益比越低杠杆越低 | 0.32× | 1.23× |
8季度趋势，按日历期对齐
现金及短期投资ICCCQDEL
| Q3 25 | $3.9M | $98.1M | ||
| Q2 25 | — | $151.7M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | $3.8M | $98.3M | ||
| Q3 24 | — | $143.7M | ||
| Q2 24 | $1.3M | $107.0M | ||
| Q1 24 | $960.3K | $78.5M | ||
| Q4 23 | $978.7K | $167.3M |
总债务ICCCQDEL
| Q3 25 | $9.5M | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | $8.7M | $2.1B | ||
| Q4 24 | $9.0M | $2.1B | ||
| Q3 24 | $9.4M | $2.2B | ||
| Q2 24 | $9.8M | $2.2B | ||
| Q1 24 | $10.2M | $2.2B | ||
| Q4 23 | $10.5M | $2.3B |
股东权益ICCCQDEL
| Q3 25 | $29.8M | $2.0B | ||
| Q2 25 | $29.9M | $2.8B | ||
| Q1 25 | $29.0M | $3.0B | ||
| Q4 24 | $27.5M | $3.0B | ||
| Q3 24 | $26.4M | $3.2B | ||
| Q2 24 | $23.5M | $3.2B | ||
| Q1 24 | $24.6M | $3.3B | ||
| Q4 23 | $25.0M | $5.0B |
总资产ICCCQDEL
| Q3 25 | $45.7M | $5.7B | ||
| Q2 25 | $46.7M | $6.4B | ||
| Q1 25 | $45.6M | $6.5B | ||
| Q4 24 | $45.1M | $6.4B | ||
| Q3 24 | $44.4M | $6.8B | ||
| Q2 24 | $41.9M | $6.7B | ||
| Q1 24 | $43.1M | $6.7B | ||
| Q4 23 | $43.8M | $8.6B |
负债/权益比ICCCQDEL
| Q3 25 | 0.32× | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | 0.30× | 0.70× | ||
| Q4 24 | 0.33× | 0.72× | ||
| Q3 24 | 0.36× | 0.68× | ||
| Q2 24 | 0.42× | 0.70× | ||
| Q1 24 | 0.41× | 0.68× | ||
| Q4 23 | 0.42× | 0.45× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.2M | $-45.5M |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | $-94.7M |
| 自由现金流率自由现金流/营收 | -32.3% | -13.5% |
| 资本支出强度资本支出/营收 | 10.8% | 7.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $715.4K | $-153.1M |
8季度趋势，按日历期对齐
经营现金流ICCCQDEL
| Q3 25 | $-1.2M | $-45.5M | ||
| Q2 25 | $1.6M | $-46.8M | ||
| Q1 25 | $1.6M | $65.6M | ||
| Q4 24 | $-3.1K | $63.7M | ||
| Q3 24 | $-639.3K | $117.9M | ||
| Q2 24 | $581.8K | $-97.9M | ||
| Q1 24 | $418.5K | $-700.0K | ||
| Q4 23 | $-723.1K | $80.4M |
自由现金流ICCCQDEL
| Q3 25 | $-1.8M | $-94.7M | ||
| Q2 25 | $1.4M | $-84.3M | ||
| Q1 25 | $1.2M | $9.4M | ||
| Q4 24 | $-199.3K | $16.5M | ||
| Q3 24 | $-727.7K | $71.4M | ||
| Q2 24 | $471.0K | $-133.2M | ||
| Q1 24 | $348.1K | $-66.8M | ||
| Q4 23 | $-804.4K | $31.8M |
自由现金流率ICCCQDEL
| Q3 25 | -32.3% | -13.5% | ||
| Q2 25 | 22.4% | -13.7% | ||
| Q1 25 | 15.4% | 1.4% | ||
| Q4 24 | -2.6% | 2.3% | ||
| Q3 24 | -12.1% | 9.8% | ||
| Q2 24 | 8.6% | -20.9% | ||
| Q1 24 | 4.8% | -9.4% | ||
| Q4 23 | -15.8% | 4.3% |
资本支出强度ICCCQDEL
| Q3 25 | 10.8% | 7.0% | ||
| Q2 25 | 2.4% | 6.1% | ||
| Q1 25 | 4.1% | 8.1% | ||
| Q4 24 | 2.5% | 6.7% | ||
| Q3 24 | 1.5% | 6.4% | ||
| Q2 24 | 2.0% | 5.5% | ||
| Q1 24 | 1.0% | 9.3% | ||
| Q4 23 | 1.6% | 6.5% |
现金转化率ICCCQDEL
| Q3 25 | — | — | ||
| Q2 25 | 3.19× | — | ||
| Q1 25 | 1.09× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | 11.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICCC
暂无分部数据
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
